Chart of the Week: Innovative Biopharma = Faster Biomarkers to Trial

by

few months ago we investigated the use of unique biomarkers by big biopharma.  The use of unique biomarkers served as a measure of innovation for each of the biggest biopharma companies.  The most innovative companies are progressing biomarkers to trials more quickly than their less innovative competitors.  In fact, on average, innovative biopharma companies are applying biomarkers to trials more than 2 years earlier than their less innovative competitors.

Biomarker_Time-to-clinic.jpg

Share this Image On Your Site

<p><strong>Please include attribution to amplion.com with this graphic.</strong><br /><br /><a href=’http://www.amplion.com/biomarker-trends/chart-of-the-week-innovative-biopharma-use-biomarkers-2-years-faster’><img src=’https://www.amplion.com/wp-content/uploads/2016/04/Biomarker_Time-to-clinic.jpg’ alt=” width=’540px’ border=’0′ /></a></p>

Do you need similar analysis for your projects?

TALK TO A CONSULTANT

PageLines

Real-Time COVID R&D Tracking

As COVID-19 infections continue to spread, organizations with technologies or devices that can support new drug, vaccine, or test development have a life-saving contribution to make. The Amplion Intelligence Platform can alert you to new COVID-19 trial activities in real-time and automatically match you to partners who need your unique capabilities immediately. It’s already tomorrow somewhere, so let us help you start today.  Learn More

Request Access